An event to engage scientists, clinicians, industry, funders, and community representatives on how best to learn from past efficacy trials to inform future vaccine development efforts.
Today, the Journal of the International AIDS Society (JIAS) commemorates HIV Vaccine Awareness Day and reflects on the long-standing efforts to develop an HIV vaccine and the significance of SARS-CoV-2 vaccine development over the past year for the future of HIV vaccine research.
Established in 2003, the Global HIV Vaccine Enterprise (the Enterprise) became a programme of IAS – the International AIDS Society – in 2018. The Enterprise unites stakeholders to share knowledge, foster collaboration, enable solutions and expand support critical to the development of – and future access to – an HIV vaccine.
Global HIV Vaccine Enterprise
IAS – the International AIDS Society
Avenue de France 23